Skip to main content

Advertisement

SpringerLink
Log in

PROSTATE CANCER

Pembrolizumab: patient selection or immune intensification?

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) have had limited clinical impact in prostate cancer. To find a niche for immune checkpoint inhibition in this disease, future strategies might require improved biomarker-based patient selection or combination strategies to enhance in vivo immune activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Biomarker-based patient selection and immune intensification.

References

  1. Boyiadzis, M. M. et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J. Immunother. Cancer 6, 35 (2018).

    Article  Google Scholar 

  2. De Bono, J. S. et al. KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J. Clin. Oncol. 36, 5007 (2018).

    Article  Google Scholar 

  3. Boudadi, K. et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9, 28561–28571 (2018).

    Article  Google Scholar 

  4. Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).

    Article  CAS  Google Scholar 

  5. US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03061539 (2017).

  6. Wu, Y. M. et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173, 1770–1782 (2018).

    Article  CAS  Google Scholar 

  7. Cordes, L. M., Gulley, J. L. & Madan, R. A. Perspectives on the clinical development of immunotherapy in prostate cancer. Asian J. Androl 20, 253–259 (2018).

    Article  Google Scholar 

  8. McNeel, D. G. et al. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget 9, 25586–25596 (2018).

    Article  Google Scholar 

  9. Stein, M. N. et al. KEYNOTE-046: ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J. Clin. Oncol. 36, 5019 (2018).

    Article  Google Scholar 

  10. US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03493945 (2018).

Download references

Author information

Authors and Affiliations

  1. Genitourinary Malignancies Branch, Centre for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA

    Ravi A. Madan & James L. Gulley

Authors
  1. Ravi A. Madan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James L. Gulley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James L. Gulley.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Madan, R.A., Gulley, J.L. Pembrolizumab: patient selection or immune intensification?. Nat Rev Urol 15, 593–594 (2018). https://doi.org/10.1038/s41585-018-0076-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-018-0076-z

  • Springer Nature Limited

Search

Navigation